Ambry Claims Myriad Is Monopolizing Breast Cancer Market
This article is for subscribers only.
Ambry Genetics Corp., a seller of tests for genetic risks of breast cancer, accused Myriad Genetics Inc. of misusing its patents to “intimidate and chill competition” in the market.
Myriad sued Ambry and another closely held company, Houston-based Gene By Gene Ltd., in July, claiming their tests infringe its patents for the testing process and synthesized DNA. The tests look at genes known as BRCA to determine if there is a hereditary risk of developing breast or ovarian cancers.